Seaport Therapeutics has secured $225m in Series B funding to advance neuropsychiatric solutions developed through its Glyph™ technology platform. The financing takes the total capital raised by the firm to $325m since launching in April. Seaport is using its Glyph technology to produce prodrugs to treat a variety of neuropsychiatric disorders such as anxious depression. The Glyph platform increases oral bioavailability and reduces hepatotoxicity and other side effects.
Volkswagen Allegedly Hit by Ransomware Attack as 8Base Claims Sensitive Data Theft
Volkswagen Group has issued a statement addressing claims by the ransomware group 8Base, which alleges it has stolen and leaked sensitive data from the automaker.
![How retraining the physician mindset can boost resilience and joy in medicine [PODCAST]](https://i1.wp.com/kevinmd.com/wp-content/uploads/Design-4-scaled.jpg?w=0&resize=0,0&ssl=1 "How retraining the physician mindset can boost resilience and joy in medicine [PODCAST]")